Related Experiment Video
Updated: Aug 7, 2026
Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death
Published on: October 21, 2012
Targeting cancer cell death with a bcl-XS adenovirus
1Department of Internal Medicine, University of Michigan Medical School, Comprehensive Cancer Center, Ann Arbor 48109, USA.
Abstract:
Transformation is a complex cellular process that requires several genetic abnormalities. In many cases, one of these abnormalities is an inhibition of PCD, which provides a selective advantage for tumor cells. This has been recently shown in an in vivo model, where overexpression of Bcl-XL, is a crucial step in the progression from hyperplasia to neoplasia and is accompanied by a significant decrease in tumor apoptosis [56]. Frequently, overexpression of a member of the Bcl-2 family results in a block in cell death and appears to nullify many built-in cellular defense mechanisms against cancer. Such a block presents a problem because radiation and chemotherapy, standard cancer treatments, ultimately exert their effect by induction of apoptosis and would also be made less effective. Therefore, to better treat cancer it may be necessary to develop novel methods to overcome the effects of the Bcl-2 family. One way to approach this problem is to target the cause--the molecular machinery that allows a cancer cell to survive. Advances in our understanding of apoptosis has identified the Bcl-2 family as a mediator of most apoptosis pathways, including those initiated by oncogenes, tumor suppressor genes, growth factor withdrawal, and external damaging signals. Therefore, functional inhibition of Bcl-2 family members is lethal to many cancer cells. Using gene transfer technology, we can now deliver genes that accomplish this goal. Further investigation will reveal whether this translates to improved therapy in the future.
Insights
Inhibiting programmed cell death (PCD) through Bcl-2 family proteins aids cancer cell survival. Targeting these proteins offers a potential strategy to enhance cancer therapies by inducing apoptosis in tumor cells.
Area of Science:
- Cellular Biology
- Molecular Oncology
- Cancer Therapeutics
Background:
- Cancer development involves genetic abnormalities, including the inhibition of programmed cell death (PCD).
- Overexpression of Bcl-2 family proteins, like Bcl-XL, promotes cancer cell survival by blocking apoptosis.
- This blockage reduces the efficacy of standard cancer treatments such as radiation and chemotherapy, which rely on inducing apoptosis.
Purpose of the Study:
- To explore strategies for overcoming the anti-apoptotic effects of Bcl-2 family proteins in cancer.
- To investigate the role of Bcl-2 family members as mediators of apoptosis pathways.
- To assess the potential of targeting Bcl-2 family proteins for novel cancer therapies.
Main Methods:
- Review of existing literature on apoptosis, Bcl-2 family proteins, and cancer development.
- Analysis of in vivo models demonstrating the role of Bcl-XL in hyperplasia to neoplasia progression.
- Discussion of gene transfer technology as a method for functional inhibition of Bcl-2 family members.
Main Results:
- Inhibition of PCD, often via Bcl-2 family overexpression, confers a survival advantage to tumor cells.
- Bcl-2 family proteins are central mediators of apoptosis, responding to various cancer-inducing signals.
- Functional inhibition of Bcl-2 family members has been shown to be lethal to many cancer cells.
Conclusions:
- The Bcl-2 family represents a critical target for cancer therapy due to its role in blocking apoptosis.
- Gene transfer technology offers a promising avenue for delivering genes that inhibit Bcl-2 family function.
- Further research is needed to translate these findings into effective clinical cancer treatments.
